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OBJECTIVES: The purpose of our study is to investigate whether the time of onset
of an acute cerebrovascular event demonstrates a seasonal variation, and we also
examined the influence of certain meteorological factors on the occurrence of this
event. METHODS: Patients admitted to the Departments of Neurology in Hungary
between 2005 and 2007 with the diagnosis of a cerebral hemorrhage (n11,604) or
a transient ischemic attack (n12,513) were examined. For data collection we used
the database of the Hungarian National Health Insurance Fund Administration
(OEP) on the basis of International Classification of Diseases (ICD). Meteorological
data (temperature, atmospheric pressure, relative humidity) was retrieved from
the National Meteorology Service. Statistical analysis was carried out with SPSS
14.0 for Windows. RESULTS: The analysis of meteorological data showed that an
increase in average temperature on the previous day resulted in a notable drop of
cerebral hemorrhage incidence during all seasons (p0.05), while in case of tran-
sient ischemic attack such a decrease only occurred during Summer (p0.05). We
have not found demonstrable influence while examining atmospheric pressure
and relative humidity. CONCLUSIONS: To summarize, we can say that our results
indicate that the incidence of cerebral infarction, cerebral hemorrhage, and a tran-
sient ischemic attack show a typical variation depending on the season of the year.
We can also say that the values of temperature may influence the development of
different cerebrovascular events.
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TYPE 2 DIABETES MELLITUS: EVIDENCE FROM A DUTCH COHORT
Heintjes E1, Penning-van Beest FJA2, Parasuraman SV3, Grandy S3, Pollack M3,
Herings RMC1
1PHARMO Institute, Utrecht, The Netherlands, 2PHARMO Institute for Drug Outcomes Research,
Utrecht, The Netherlands, 3AstraZeneca, Wilmington, DE, USA
OBJECTIVES: To determine the population attributable risk (PAR) of macrovascular
events associated with HbA1c, systolic blood pressure (SBP), or weight (BMI) in
patients with type 2 diabetes mellitus (T2DM). METHODS: The population-based
PHARMO database contains T2DM patients regularly monitored in primary care for
cardiovascular risk factors HbA1c, SBP and BMI. In the period 2000-2008 patients
without baseline macrovascular events and on antidiabetic treatment for 6
months were followed from start of monitoring until monitoring ended. Multivar-
iate survival modeling of the composite outcome of macrovascular events was
used to estimate the expected number of events after 5 years, either with un-
changed risk factors (base-case) or with reductions in risk factors. The PAR was
calculated as the number of averted events divided by the number of expected
events in the base-case analysis. RESULTS:Mean age of 5841 included patients was
66 years (55% male), 45% had HbA1c levels 7%, 66% had a SBP 140 mmHg and
85% had a BMI25 kg/m2. The base case expected number of macrovascular events
at 5 years was 796, and 687 after reduction to target of all 3 risk factors. The com-
bined PAR of elevated HbA1c, SBP and BMI was 14%, ranging from 5% among those
with one elevated risk factor to 21% among those with three risk factors elevated.
Incremental reductions of 0.5% HbA1c, 10mmHg SBP and 10% BMI led to 4% fewer
events, ranging from 2-10%. The PAR of reducing HbA1c to target (7%) was 5%,
ranging from 2-10%. The PAR of reducing SBP to target (135 mmHg) was 9%, ranging
from 3-12%. There was no effect of reduction in BMI alone. CONCLUSIONS: Reduc-
ing elevated HbA1c and blood pressure levels was associated with improvements
in cardiovascular risk. Even modest reductions in risk factors lead to significant
reductions in macrovascular events in T2DM patients.
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OBJECTIVES: To report on the goal rates for SBP, plasma lipid variables, and body
mass index (BMI), based on published guidelines, from data available in the 2nd
quarter (Q2) post-baseline of the GVRM initiative; a 5-year project focusing on
validating the COSEHC risk score through cardiovascular risk factor management.
METHODS: The Consortium for Southeastern Hypertension Control (COSEHC) de-
veloped a risk score tool to predict cardiovascular disease (CVD) mortality in the
southeastern (SE) US. This global approach to SE CVD calculates the absolute risk
for 5-year CVD mortality based on: age, sex, total, HDL and LDL-cholesterol, trig-
lycerides (TG), SBP, and evidence of smoking, diabetes, family history of CHD, and
ECG-confirmed cardiac hypertrophy. Baseline data were obtained from 78,540 pa-
tients (42,707 females) across ten medical facilities. RESULTS: From 39,080 females
and 33,144 males with Q2 data at goal for SBP (63 vs. 70%), LDL-cholesterol (41 vs. 55
%), TG (59 vs. 57%), and % of non-smokers were similar between the two sexes.
Female subjects, however, achieved higher at goal targets for HDL-cholesterol (63
vs. 36% in males, p 0.05) and BMI (22 vs. 16 in males, p 0.003). In addition, at goal
rates for SBP control correlated with improved HDL-cholesterol (r0.64, p 0.05)
and weight values in females (r -0.69, p 0.05) and only weight in males (r -0.76,
p  0.05). COSEHC 5-year absolute risk scores for CVD mortality in the entire pop-
ulation were higher in males [(Mean SD) 36.43 2.26] compared to females (30.57
 3.38, p  0.0005). CONCLUSIONS: The GVRM initiative provides an effective way
of benchmarking risk factors in a population at high risk for cardiovascular events.
The initiative is assisting health care providers to monitor risk factors at regular
intervals and proactively manage the cardiovascular risk of their patient popula-
tion.
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SAFETY AND TOLERABILITY OF BISOPROLOL COMPARED TO ATENOLOL IN
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OBJECTIVES: The objective was to evaluate the safety and tolerability of bisoprolol
compared to atenolol in patients with essential mild to moderate hypertension.
METHODS: Studies were retrieved from Embase, Pubmed, and Cochrane databases
using relevant search strategies. Randomised controlled trials which compared
bisoprolol with atenolol were included according to pre-specified inclusion/exclu-
sion criteria. The outcomes of interest were total withdrawals from study, with-
drawals due to adverse events (AE), withdrawals due to lack of efficacy, any adverse
events, bradycardia, fatigue, oedema and vertigo. Two reviewers independently
extracted data from the included studies. Data was meta-analysed using RevMan
(5). RESULTS:Of the 1056 studies identified, 11 studies met the inclusion criteria. In
total, 624 patients were randomised to bisoprolol, and 683 were randomised to
atenolol. Seven of the included studies were double-blind, three were single-blind
and one was open-label study. The Jadad score of eight studies was3 and were of
good quality. The study duration of included studies ranged from 8-weeks to 52-
weeks. Results of meta-analysis showed that with bisoprolol there was lower risk
of study withdrawals [RR: 0.95 (0.79, 1.16)] and withdrawals due to lack of efficacy
[RR: 0.58 (0.14, 2.37)] as compared to atenolol. Withdrawals due to AE were more in
the bisoprolol group compared to atenolol. The risk of AE (any) was lower with
atenolol compared to atenolol [RR: 0.94 (0.73, 1.21)]. The risk of bradycardia was
higher with bisoprolol compared to atenolol (p0.3). Lower risk of oedema (p0.3)
and vertigo (p0.6) was reported with bisoprolol as compared to atenolol.
CONCLUSIONS: This review has included the evidence to date with regards to
safety and tolerability of bisoprolol compared to atenolol. This review concludes
that availability of bisoprolol provides the patients with a safe and efficacious
first-line therapy option in hypertension.
PCV36
HIGH DOSE AND LONG-TERM SAFETY OF SYSTEMIC CORTICOSTEROIDS IN THE
TREATMENT OF POLYMYLAGIA RHEUMATICA AND VASCULITIS: A
SYSTEMATIC REVIEW
Nyssen OP1, Gauthier A1, Schmitt C2, Levy V2, Cognet M1, Aguiar-ibanez R1
1Amaris Consulting UK, London, UK, 2GlaxoSmithKline, London, UK
OBJECTIVES: To review the evidence base for the safety of high dose and long-term
usage of systemic corticosteroids (CSs). METHODS: Selection of studies: popula-
tion-based studies involving patients with polymyalgia rheumatica or vasculitis
treated with systemic CSs and reporting the incidence of diabetes, hypertension,
cataract, osteoporosis or cardiovascular events. Search strategy: A systematic lit-
erature review was conducted in Medline, Medline-in-process, Embase, and the
Cochrane Library up to January 2011, with very broad search terms in order to limit
the risk of missing relevant studies. Data synthesis: “Key studies” were identified as
assessing comparisons relevant to our study question (CSs vs. no use of CSs and/or
assessment of CSs at different doses) and reporting at least one outcome of interest
by treatment group. Results were summarized separately for key studies and other
studies. RESULTS: Out of 3671 citations initially identified for screening 76 publi-
cations were selected. Few studies were identified as key: only 3 reported the inci-
dence of diabetes, hypertension or cardio-vascular events, four studies docu-
mented the development of cataract and seven reported outcomes related to
osteoporosis. Based on these studies, outcomes such as cataract and osteoporosis
presented a higher rate of incidence for both indications within the CSs treatment
groups, and tended to be less common when the treatment arm combined intra-
venous or intramuscular CSs with oral CSs than with oral CSs alone. No significant
association was found for the other outcomes of interest. The magnitude of the CSs
effect on the outcomes of interest varied greatly between studies. CONCLUSIONS:
Although CSs are a cornerstone of treating polymyalgia rheumatica and vasculitis,
the evidence base for their safety profile is poor, subject to a high level of hetero-
geneity, and the findings for the different outcomes were not always consistent
across studies, demonstrating the need for further research in this area.
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OBJECTIVES: The risk of subsequent events after a first cardiovascular event in
persons with type 2 diabetes has received less attention to date. Simulation mod-
els, including risk engines and health-economic cost-effectiveness models, have
thus relied primarily on estimations of the risk of first events and assumed con-
stant transition probabilities for subsequent events. The aim of the current study is
to analyze the differences in risk of having a first and a second myocardial infarc-
tion (MI) for persons with type 2 diabetes. METHODS: Observational data from the
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Swedish National Diabetes Register (NDR) for 35,238 persons with type 2 diabetes
aged 30-74 years at diagnosis from January 1, 2004 to December 31, 2008 were
analyzed using the conditional non-frailty Weibull model. To not underestimate
the effect of BMI, two specifications of the model were estimated. Age at diagnosis,
sex, hypoglycaemic treatment, diabetes duration, microalbuminuria and smoking
were common covariates in both models.RESULTS:A total of 1409 patients had one
MI event and 200 experienced two events. The results showed that the risk of a
second MI differ from the risk of having a first MI. In addition, the effects of cova-
riates were not constant between multiple events. Women had a lower risk for
developing a first event compared to men, but a higher risk for a second event
conditional on the first MI. Preliminary results indicate four times higher hazard of
developing a MI conditional on a first MI during the follow up. CONCLUSIONS: The
findings show the need for an update of simulation models including health-eco-
nomic models and risk engines to include separate transition probabilities for first
and subsequent events for correct predictions of costs and quality of life gains.
Using recurrent event risk equations may reduce the bias from the previous as-
sumption of constant transition probabilities for consecutive events in health eco-
nomic models.
Cardiovascular Disorders – Cost Studies
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OBJECTIVES: To assess the health and budget impact of increasing use of rosuvas-
tatin in patients with high cardiovascular risk, while maintaining the overall level
of use, upon the entry of generic atorvastatin in Sweden. METHODS: A model was
developed to estimate the budget impact associated with changed statin utilization
pattern in different risk groups. The Framingham Risk equation was used to esti-
mate cardiovascular events, and the relative risk reduction for statins was modeled
using the JUPITER (Justification for the Use of statins in Primary prevention: an
Intervention Trial Evaluating Rosuvastatin) trial. A similar relative risk reduction
was used for primary and secondary prevention settings based on available liter-
ature. Baseline risk distribution was derived from the Malmö Primary Prevention
Study. The use of rosuvastatin was assumed to increase from 4% (2011) to 7% (2014)
in the high-risk group (27% baseline 10-year Framingham risk), but the overall use
was kept unchanged (4%). A gradual atorvastatin use increase was assumed with a
corresponding decrease in simvastatin use over 3 years. Cost calculations were
from Swedish public health sources. Generic price for atorvastatin was assumed to
be 5% of branded price. RESULTS: For the Swedish population on statin treatment
(810,304 patients, 25% with a previous history of CVD) the estimated budget impact
decreased by SEK 359 millions in 2012 (compared with 2011) and by SEK 441 mil-
lions in 2014 with changed statin utilization. The estimated number of CVD events
avoided ranged from 98 in 2012 to 197 in 2014 compared with current year (0.81%
decrease over the 3-year period). CONCLUSIONS: A shift to generic atorvastatin in
2012, accompanied by increased use of rosuvastatin in high-risk patients whilst
maintaining rosuvastatin overall use at current levels, was estimated to prevent
more cardiovascular events and resulted in overall healthcare budget savings for
the 3-year period in Sweden.
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OBJECTIVES: The antibody-mediated, prothrombotic heparin-induced thrombocy-
topenia type II (HIT-II) is a life-threatening disease with high thrombosis risk of
38-76% and up to 20% mortality. Pulmonary embolism occurs in up to 40% of pa-
tients, and amputations are necessary in up to 15%. The objective was to evaluate
frequency and cost of HIT-II in Germany. METHODS: Systematic literature
searches regarding epidemiology and cost of HIT-II were conducted until end of
2000 with Medical Subject Heading terms “incidence”, “epidemiology”, “risk”, and
“cost” each in combination with “heparin-induced thrombocytopenia”. German
secondary data were obtained by desktop research from the German Federal Sta-
tistical Office and a German university hospital. RESULTS: Literature search
yielded eleven relevant publications selected by successive title, abstract and
whole publication screening from a total of 1225 hits. Published incidence for HIT-II
in Germany was 0.039% for in-hospital patients, and average additional costs per
patient amounted to €9004 (Wilke et al., J Thromb Haemost, 2009). Data from the
German Federal Statistical Office for 2009 show an incidence of 0.05% for patients
with secondary diagnosis HIT-II, ICD-10 Code D69.53, corresponding to 8,585 cases
(age peak 65-85 years) with an average prolongation of hospital stay by 18 days. The
frequency of documented HIT-II as secondary diagnosis increased since 2005 by
60.4% (2005: 5353; 2006: 6263; 2007: 7177; 2008: 7454 cases). Estimated additional
costs generated by HIT-II in Germany in 2005 amount to 48 million euro, and in 2009
to a minimum of 77 million euro. CONCLUSIONS: Cost and burden of HIT-II are
considerable. Due to the demographic development to be expected in Germany
during the next decades in combination with the age peak of the disease a further
increase in HIT-II cases has to be anticipated. Data are limited. Further epidemio-
logical research and analysis of burden of disease from several perspectives are
needed.
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OBJECTIVES: To estimate the hospital impact with the introduction of vernakalant
in hospital emergency departments (EDs) in Spain.METHODS: Patients with recent
onset atrial fibrillation (AF) (48H) or non-permanent AF without thromboembolic
risk (anticoagulation or negative transesophageal echocardiography) were in-
cluded in the ED setting. Scenario: Data derived from the RHYTHM-AF-Spain study
or determined by the hospital. Budget impact model with the following variables:
percentage of use of anti-arrhythmic drugs (AAD) before and after the entry of
vernakalant, time to cardioversion with AAD and number of patients per year that
could be treated with vernakalant. Outcome variables: impact on pharmacy bud-
get, length of stay in ED (cost offset, additional patients treated in ED). Time to
achieve sinus rhythm for vernakalant, drug cost, and hospital stay were obtained
from published data. RESULTS: According to Spanish RHYTHM-AF study data, in
67% of these patients cardioversion (CV) is attempted with the following AAD (pro-
portion; mean time to normal sinus rhythm): amiodarone iv (55%; 7 hours), flecain-
ide iv/oral (12%/28%; 1.5/4.2 hours), propafenone iv/oral (1%/4%; 2/6.1 hours). It is
estimated that in a hospital like those enrolled in RHYTHM-AF, approximately 150
patients per year would be admitted into the ED and pharma-cardioversion would
be attempted in 101. Assuming that AADs were partially substituted for vernakal-
ant (30% for amiodarone, 15% flecainide oral, 5% flecainide iv, and 5% propafenone
oral), 22 patients would receive vernakalant per year. The annual incremental cost
is €7,772.13, but offset in 63.4% due to a reduction of 123.16 hours of stay in the ED
that would also allow for the assistance of 15 additional patients. CONCLUSIONS:
The reduction of hospital stay associated with the use of vernakalant carries a high
percentage of compensation costs associated with reduction of stay in the ED and
frees up resources to attend to more patients.
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OBJECTIVES: There has been enormous interest in the potential benefit, primarily
around decreased medical resource use, of the introduction of telehealth home
monitoring systems (THMS) for chronic disease management. Widespread adop-
tion has nevertheless been slow due to a lack of information on the financial im-
plications of implementation. THMS requires a substantial initial investment
which in a time of budget cuts needs economic justification. The objective of this
study was to provide an estimate of the potential short-term financial implications
of introducing the Care Innovations™ Guide THMS for patients with chronic heart
failure (CHF) in a typical PCT within the UK. METHODS: A one-year budget impact
model was developed looking at key financial drivers of CHF care including GP
visits, unplanned hospitalisation, ambulance time, etc. The model assessed the
impact on these costs after the introduction a THMS package for a PCT with a
population of 500,000, assuming the initial THMS uptake would be 30% of CHF
patients. Population and disease incidence and prevalence data for England were
taken from the Quality and Outcomes Framework 2009-10. Average costs per unit
of medical resource use, amount of resource use per year for a typical chronic CHF
patient receiving standard care and estimates of the impact of the THMS on re-
source use were estimated from published literature. RESULTS: The model esti-
mated that the introduction of THMS required an initial investment of £9,440,567
but yielded a return of 2% (£158,812) within one year. CONCLUSIONS: The intro-
duction of THMS requires considerable initial investment; however this model
suggests that this is offset within a very short time-frame due to reductions in
medical resource usage and is expected to lead to substantial savings over the
medium-term. This should encourage decision-makers to seriously consider mov-
ing from small pilot studies to more widespread implementation of THMS.
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OBJECTIVES:To assess the economic impact of adding SevikarHCT® to the Spanish
market for the treatment of arterial hypertension in the adult population aged over
35. SevikarHCT® concerns a new three-in-one combination tablet containing olm-
esartan medoxomil, amlodipine and hydrochlorothiazide. METHODS: To estimate
the economic impact a budget impact was developed using the Spanish national
healthcare system (NHS) perspective and a 3-year time horizon. The patient pop-
ulation was estimated based on disease prevalence, population growth and data on
the currently treated population with combinations of receptor blockers of the
antagonists of the angiotensin II (ARBII) with calcium channel blockers (CCB) alone
or together with diuretics (DIU) in fixed doses. Costs considered in this model
included drugs actually marketed or over the next three years consisting of Bal-
zak®, Balzak plus®, Capenon®, CapenonHCT®, Copalia®, CopaliaHCT®, Dafiro®,
DafiroHCT®, Exforge®, ExforgeHCT®, Imprida®, ImpridaHCT®, Twynsta®, Se-
vikar® and SevikarHCT® expressed in EUR 2010. Based on the annual drug costs
per patient and market shares for each treatment the economic burden before and
after the introduction of SevikarHCT® was estimated. A drop of 28% in drug prices
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